AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19645912 — intervention group
Group type: COMPARATOR
Intervention: Practice alone (without vibrotactile biofeedback).
Number of subjects: 0
Study 17013478 — intervention group
Group type: EXPERIMENTAL
Intervention: Open method (excision and healing by secondary intention)
Number of subjects: 77
Study 17013478 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (primary midline suturing after excision)
Number of subjects: 77
Study 15111846 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg once a day for 45 days
Number of subjects: 100
Study 15111846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15556053 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg)
Number of subjects: 10
Study 15556053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15556053 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (≤125 mg daily)
Number of subjects: 10
Study 10708172 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the pre-sedation GCS score for APACHE II and III calculations
Number of subjects: 13291
Study 10708172 — intervention group
Group type: COMPARATOR
Intervention: Assuming normal GCS score for APACHE II and III calculations
Number of subjects: 13291
Study 9105945 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced tasks (visual matrix problem solving and mirror tracing)
Number of subjects: 132
Study 9105945 — intervention group
Group type: COMPARATOR
Intervention: Externally-paced tasks (with imposed work pace requirements)
Number of subjects: 132
Study 9105945 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced tasks (mirror tracing)
Number of subjects: 132
Study 9105945 — intervention group
Group type: COMPARATOR
Intervention: Externally-paced tasks (visual matrix task)
Number of subjects: 132
Study 1491774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg single oral administration)
Number of subjects: 174
Study 1491774 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (200 mg capsules daily for 5 days)
Number of subjects: 174
Study 3100311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (1, 4, or 8 tablets, 244 mg aluminium per tablet) taken with citric acid solution
Number of subjects: 10
Study 3100311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (1, 4, or 8 tablets, 244 mg aluminium per tablet) taken with orange juice
Number of subjects: 10
Study 3100311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (4 tablets) taken with water
Number of subjects: 10
Study 3100311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (1, 4, or 8 tablets) taken with water
Number of subjects: 10
Study 3100311 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of aluminium containing antacids
Number of subjects: 10
Study 3100311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids taken with orange juice or citric acid
Number of subjects: 10
Study 29327170 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SM)
Number of subjects: 11
Study 29327170 — intervention group
Group type: COMPARATOR
Intervention: Passive Movement Control
Number of subjects: 11
Study 26814280 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily morphine (n=11)
Number of subjects: 21
Study 26814280 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (n=10)
Number of subjects: 21
Study 23548501 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video intervention (IVI)
Number of subjects: 185
Study 23548501 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 185
Study 22908326 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF therapy (SpA patients)
Number of subjects: 120
Study 22908326 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF therapy (mAbs)
Number of subjects: 120
Study 22908326 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (Anti-TNF therapy)
Number of subjects: 120
Study 22908326 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and mAb treatment
Number of subjects: 120
Study 20492876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent etanercept therapy
Number of subjects: 0
Study 20492876 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous etanercept therapy
Number of subjects: 0
Study 18639771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe-based therapy
Number of subjects: 0
Study 18639771 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study 15817189 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia patients (n = 7)
Number of subjects: 49
Study 15817189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia patients (n = 18)
Number of subjects: 49
Study 15817189 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (n = 24)
Number of subjects: 49
Study 14500118 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz rTMS at 90% of the individual motor threshold (MT) applied over the right parietal cortex for 20 min
Number of subjects: 8
Study 14500118 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 8
Study 10597850 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strengthening for quadriceps and hamstrings
Number of subjects: 17
Study 8600096 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-2123 (880 mg) with discontinuous accelerated hyperfractionated radiation
Number of subjects: 0
Study 8600096 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-2123 (990 mg) with discontinuous accelerated hyperfractionated radiation
Number of subjects: 0
Study 8600096 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinuous accelerated hyperfractionated radiation alone)
Number of subjects: 0
Study 1747056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundoplication alone (group 1)
Number of subjects: 54
Study 1747056 — intervention group
Group type: COMPARATOR
Intervention: Fundoplication with proximal gastric vagotomy (group 2)
Number of subjects: 54
Study 1747056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 54
Study 6817123 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril after diuretic (thiazide) pretreatment
Number of subjects: 350
Study 6817123 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril without diuretic (thiazide) pretreatment
Number of subjects: 350
Study 30105808 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy (EFT)
Number of subjects: 16
Study 30105808 — intervention group
Group type: COMPARATOR
Intervention: Usual care (couple therapy other than EFT)
Number of subjects: 16
Study 28910303 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and midazolam
Number of subjects: 105
Study 28910303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam
Number of subjects: 105
Study 28910303 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (control group)
Number of subjects: 105
Study 26224886 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day hypocaloric diet (‐500 kcal/day) low in saturated fat (<7% of energy)
Number of subjects: 15
Study 26224886 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet with usual amount of saturated fat (10% of energy)
Number of subjects: 15
Study 23758233 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled racemic adrenaline
Number of subjects: 404
Study 23758233 — intervention group
Group type: COMPARATOR
Intervention: Inhaled saline
Number of subjects: 404
Study 23758233 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand inhalation
Number of subjects: 404
Study 23758233 — intervention group
Group type: COMPARATOR
Intervention: Fixed-schedule inhalation
Number of subjects: 404
Study 21821813 — intervention group
Group type: COMPARATOR
Intervention: Oat silage‐based diet containing starch (HS) from dry rolled corn (DRC)
Number of subjects: 0
Study 21821813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat silage‐based diet containing digestible fiber (HF) from soybean hulls (SBH)
Number of subjects: 0
Study 19249410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g daily of omega‐3‐acid ethyl esters
Number of subjects: 1400
Study 19249410 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 1400
Study 17288648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based and cognitive restructuring therapy
Number of subjects: 16
Study 17288648 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting-list subthreshold PTSD patients)
Number of subjects: 16
Study 16279283 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of folic acid, vitamin B6, and vitamin B12
Number of subjects: 2006
Study 12390056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg daily
Number of subjects: 41
Study 12390056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol 400 IU daily
Number of subjects: 41
Study 12390056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg daily plus tocopherol 400 IU daily
Number of subjects: 41
Study 12390056 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study 9836032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg.kg‐1; n = 20)
Number of subjects: 41
Study 9836032 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.5 mg.kg‐1; n = 21)
Number of subjects: 41
Study 7859455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 230
Study 7859455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 230
Study 2804866 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational techniques
Number of subjects: 20
Study 2804866 — intervention group
Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 20
Study 786022 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin
Number of subjects: 54
Study 786022 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin and kanamycin
Number of subjects: 54
Study 6180050 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of human fibroblast-derived (beta) interferon (HulFN-beta) at a total of 1-2 x 10(5) reference units per day, divided into 8-10 drops.
Number of subjects: 0
Study 6180050 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of human fibroblast-derived (beta) interferon (HulFN-beta)
Number of subjects: 0
Study 6180050 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid therapy or placebo containing human serum albumin, with the same administration schedule.
Number of subjects: 0
Study 6180050 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses of interferon lower than 5 x 10(4) units per day
Number of subjects: 0
Study 31730466 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging (WB-MRI)
Number of subjects: 0
Study 31730466 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 0
Study 29362205 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with drug risk information
Number of subjects: 2125
Study 29362205 — intervention group
Group type: COMPARATOR
Intervention: Video without drug risk information
Number of subjects: 2125
Study 29362205 — intervention group
Group type: EXPERIMENTAL
Intervention: Any video
Number of subjects: 2125
Study 29362205 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with risk information
Number of subjects: 2125
Study 29362205 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk vs Non-risk video conditions
Number of subjects: 2125
Study 26577688 — intervention group
Group type: EXPERIMENTAL
Intervention: Karate techniques training for 14 weeks
Number of subjects: 30
Study 26577688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 25011661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (16°C)
Number of subjects: 12
Study 22146002 — intervention group
Group type: EXPERIMENTAL
Intervention: Circum brush (CB)
Number of subjects: 8
Study 22146002 — intervention group
Group type: COMPARATOR
Intervention: Straight soft interdental brush (SB)
Number of subjects: 8
Study 20812037 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Migraine Management+
Number of subjects: 176
Study 20812037 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Migraine Management-
Number of subjects: 176
Study 20812037 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker
Number of subjects: 176
Study 20812037 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 176
Study 17515403 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based chemotherapy
Number of subjects: 823
Study 12619921 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 2.5 U/day
Number of subjects: 80
Study 12619921 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 1.0 U/day
Number of subjects: 80
Study 12619921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10705774 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous regression procedure
Number of subjects: 0
Study 10705774 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-stage regression method
Number of subjects: 0
Study 10705774 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel regression method
Number of subjects: 0
Study 10705774 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9171127 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrosurgery with metal cannulas
Number of subjects: 19
Study 9171127 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrosurgery with plastic cannulas
Number of subjects: 19
Study 9171127 — intervention group
Group type: COMPARATOR
Intervention: Control (no electrosurgery)
Number of subjects: 19
Study 8471372 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 150 mg/24 h
Number of subjects: 90
Study 8471372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg/24 h
Number of subjects: 90
Study 8471372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3542772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (5 ng/kg/min infused i.v. for 5 hrs per day during 6 consecutive days)
Number of subjects: 30
Study 3542772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 30
Study 3542772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28589894 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal expressing (expressing breastmilk twice per day from 36 weeks' gestation)
Number of subjects: 635
Study 28589894 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual midwifery and obstetric care, supplemented by support from a diabetes educator)
Number of subjects: 635
Study 28589894 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal expressing
Number of subjects: 635
Study 28589894 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 635
Study 25979833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 399
Study 25979833 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 399
Study 23359491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 1,000 mg BID plus Peg‐IFNα‐2a/RBV
Number of subjects: 166
Study 23359491 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Peg‐IFNα‐2a/RBV
Number of subjects: 166
Study 22045821 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Colonoscopy (TC)
Number of subjects: 12039
Study 22045821 — intervention group
Group type: COMPARATOR
Intervention: Flexible Sigmoidoscopy (FS)
Number of subjects: 12039
Study 22045821 — intervention group
Group type: COMPARATOR
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 12039
Study 18614144 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of IVH
Number of subjects: 366
Study 18614144 — intervention group
Group type: COMPARATOR
Intervention: Open repair of IVH
Number of subjects: 366
Study 18614144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both laparoscopic and open repair
Number of subjects: 366
Study 17577169 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging questions asked by interviewers
Number of subjects: 40
Study 15355148 — intervention group
Group type: EXPERIMENTAL
Intervention: Versions of the Monty Hall dilemma involving competition that emphasizes causality
Number of subjects: 0
Study 15355148 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the collider principle
Number of subjects: 0
Study 15355148 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct responses to questions about the MHD process
Number of subjects: 0
Study 11565729 — intervention group
Group type: EXPERIMENTAL
Intervention: Allon thermoregulation (AT)
Number of subjects: 60
Study 11565729 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal care (RTC)
Number of subjects: 60
Study 9093678 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Impulse Test (HIT)
Number of subjects: 105
Study 9093678 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Shake Nystagmus (HSN)
Number of subjects: 105
Study 9093678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HIT and HSN
Number of subjects: 105
Study 8203844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily for 3 days (multiple-dose administration)
Number of subjects: 20
Study 8203844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg as a single dose (single-dose administration)
Number of subjects: 20
Study 8203844 — intervention group
Group type: COMPARATOR
Intervention: Fleroxacin administered in a fed state
Number of subjects: 20
Study 2450234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0
Study 2450234 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 2450234 — intervention group
Group type: COMPARATOR
Intervention: Intergroup comparison
Number of subjects: 0
Study 31430034 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful CTO-PCI
Number of subjects: 460
Study 31430034 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete coronary revascularization
Number of subjects: 460
Study 31430034 — intervention group
Group type: COMPARATOR
Intervention: Failed CTO-PCI
Number of subjects: 460
Study 31430034 — intervention group
Group type: COMPARATOR
Intervention: Incomplete revascularization
Number of subjects: 460
Study 31338868 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2-1.8 mg/d for 26 weeks)
Number of subjects: 39
Study 31338868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28982906 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) only
Number of subjects: 180
Study 28982906 — intervention group
Group type: EXPERIMENTAL
Intervention: GA with single-injection thoracic paravertebral block (s-TPVB)
Number of subjects: 180
Study 28982906 — intervention group
Group type: EXPERIMENTAL
Intervention: GA with continuous thoracic paravertebral block (c-TPVB)
Number of subjects: 180
Study 25028082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-g milk-LNS
Number of subjects: 1053
Study 25028082 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-g milk-LNS
Number of subjects: 1053
Study 25028082 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-g non-milk-LNS
Number of subjects: 1053
Study 25028082 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-g milk-LNS
Number of subjects: 1053
Study 25028082 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-g non-milk-LNS
Number of subjects: 1053
Study 25028082 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1053
Study 23456732 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV400 (400 mg once daily)
Number of subjects: 200
Study 23456732 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV300/r (300 mg ATV plus 100 mg ritonavir once daily)
Number of subjects: 200
Study 23456732 — intervention group
Group type: COMPARATOR
Intervention: ATV400 and ATV300/r
Number of subjects: 200
Study 23456732 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV300/r
Number of subjects: 200
Study 20817749 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 16
Study 20817749 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (4, 6, and 6 mg, vaporized and inhaled)
Number of subjects: 16
Study 20817749 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of MDMA and THC
Number of subjects: 16
Study 20817749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19175841 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-catheter approach (group 1)
Number of subjects: 110
Study 19175841 — intervention group
Group type: COMPARATOR
Intervention: Double-catheter approach (group 2)
Number of subjects: 110
Study 17504540 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient aftercare
Number of subjects: 4165
Study 17504540 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential aftercare
Number of subjects: 4165
Study 15006036 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining sleep
Number of subjects: 0
Study 15006036 — intervention group
Group type: COMPARATOR
Intervention: Posttraining sleep deprivation
Number of subjects: 0
Study 11890362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezlopitant
Number of subjects: 14
Study 9589229 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of water with 25 g glucose
Number of subjects: 8
Study 9589229 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml of water with 25 g glucose
Number of subjects: 8
Study 9589229 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of water with 25 g sucrose
Number of subjects: 8
Study 9589229 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml of water with 25 g sucrose
Number of subjects: 8
Study 9589229 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of water with 25 g fructose
Number of subjects: 8
Study 9589229 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml of water with 25 g fructose
Number of subjects: 8